Please login to the form below

Not currently logged in
Email:
Password:

metreleptin

This page shows the latest metreleptin news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar and Xeljanz

Aegerion’s rare disease drug approved. Specialist pharma company Aegerion has gained European approval for Myalepta (metreleptin) for the ultra-rare condition, lipodystrophy.

Latest news

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics